Action Calliditas Therapeutics Ab - 0A5R

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy PR Newswire STOCKHOLM, Aug. 18, 2023 STOCKHOLM, Aug. 18, 2023 /PRNewswire/ -- Calliditas Therapeutics...

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy PR Newswire STOCKHOLM, Aug. 18, 2023 STOCKHOLM, Aug. 18, 2023 /PRNewswire/ -- Calliditas Therapeutics...

Interim Report Q2, 2023: Calliditas Therapeutics

Interim Report Q2, 2023: Calliditas Therapeutics PR Newswire STOCKHOLM, Aug. 17, 2023 Filing for full approval of TARPEYO STOCKHOLM, Aug. 17, 2023 /PRNewswire/ -- FINANCIAL SUMMARY FOR THE...

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet PR Newswire STOCKHOLM, Aug. 15, 2023 STOCKHOLM, Aug. 15, 2023 /PRNewswire/ -- Calliditas...

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet PR Newswire STOCKHOLM, Aug. 15, 2023 STOCKHOLM, Aug. 15, 2023 /PRNewswire/ -- Calliditas...

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR Newswire STOCKHOLM, July 13, 2023 STOCKHOLM, July 13, 2023...

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR Newswire STOCKHOLM, July 13, 2023 STOCKHOLM, July 13, 2023...

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® PR Newswire STOCKHOLM, June 21, 2023 STOCKHOLM, June 21, 2023...

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® PR Newswire STOCKHOLM, June 21, 2023 STOCKHOLM, June 21, 2023...

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, May 30, 2023 STOCKHOLM, May 30, 2023 /PRNewswire/ -- The following resolutions were passed at...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0A5R - Frequently Asked Questions (FAQ)

What is the current Calliditas Therapeutics Ab share price?

The current share price of Calliditas Therapeutics Ab is SEK 0,00

What is the 1 year trading range for Calliditas Therapeutics Ab share price?

Calliditas Therapeutics Ab has traded in the range of SEK 0,00 to SEK 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
TIRTiger Royalties And Investments Plc	0,15p (50,00%)	3,41M
BAYBay Capital Plc	5,50p (19,57%)	209,68k
MASTMast Energy Developments Plc	0,19p (18,75%)	20,09M
MHNMenhaden Resource Efficiency Plc	148,50p (18,33%)	1M
ZENZenith Energy Ltd.	2,50p (16,28%)	3,93M
TRYBTribe Technology Plc	0,115p (-79,09%)	24,27M
NMTNeometals Ltd	2,75p (-35,29%)	49,4k
SNGSynairgen Plc	2,46p (-34,31%)	4,31M
TM1Technology Minerals Plc	0,185p (-26,00%)	174,03M
AYMAnglesey Mining Plc	0,70p (-17,65%)	2,99M
NTVONativo Resources Plc	0,002p (5,26%)	971,94M
TRPTower Resources Plc	0,035p (9,38%)	620,03M
LLOYLloyds Banking Group Plc	54,16p (-0,26%)	341,48M
ORCPOracle Power Plc	0,0255p (-1,92%)	192,93M
TM1Technology Minerals Plc	0,185p (-26,00%)	174,03M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Calliditas Therapeutics Ab (0A5R)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

0A5R Dernières nouvelles

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

Interim Report Q2, 2023: Calliditas Therapeutics

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

0A5R - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Calliditas Therapeutics Ab (0A5R) Cours

Calliditas Therapeutics Ab (0A5R)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

0A5R Dernières nouvelles

0A5R - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE